Leiomyosarcoma of the cervix uteri

Leiomyosarcoma of the cervix uteri is an extremely rare malignant soft tissue tumor arising from the smooth muscle cells of the uterine cervix. It belongs to the broader category of uterine sarcomas but is distinguished by its specific cervical location, which accounts for only a very small fraction of all cervical malignancies. The tumor typically presents as a rapidly growing cervical mass and may cause symptoms such as abnormal vaginal bleeding (including postmenopausal bleeding), pelvic pain or pressure, vaginal discharge, and dyspareunia. Due to its location, it may also cause urinary or bowel symptoms if the mass compresses adjacent structures. Diagnosis is often made after surgical excision or biopsy, as preoperative distinction from benign cervical leiomyomas can be challenging. The primary treatment for leiomyosarcoma of the cervix uteri is surgical resection, which may include radical hysterectomy with or without removal of surrounding tissues and lymph nodes, depending on the stage of disease. Adjuvant therapies such as radiation therapy and chemotherapy (commonly doxorubicin-based regimens) may be considered, particularly in cases with advanced or recurrent disease, though evidence for their efficacy in this specific location is limited due to the rarity of the condition. Prognosis varies depending on tumor size, stage at diagnosis, mitotic index, and completeness of surgical resection. Because of its rarity, much of the clinical management is extrapolated from data on uterine corpus leiomyosarcomas and other soft tissue sarcomas. Long-term follow-up is essential due to the risk of local recurrence and distant metastasis, most commonly to the lungs and liver.

Common questions about Leiomyosarcoma of the cervix uteri